Lyumjev (insulin lispro-aabc) for the Treatment of Type 1 and Type 2 Diabetes
Lyumjev™ (insulin lispro-aabc) is rapid-acting insulin indicated to enhance glucose control in adults with type 1 and type 2 diabetes.
Taltz (ixekizumab) for the Treatment of Non-Radiographic Axial Spondyloarthritis
Taltz® (ixekizumab) is the first humanised interleukin (IL)-17A antagonist therapy approved for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective inflammation signs.
Study: Pharmacokinetics of Oral Cyanocobalamin Formulated with SNAC
riginally published by Elsevier Journals on 24 May 2011, this white paper outlines an open-label, randomised, single-dose, parallel-group study of the pharmacokinetics of oral cyanocobalamin formulated with Sodium N-[8-(2-hydroxy benzoyl) amino] caprylate (SNAC).
Coronavirus treatment: Vaccines/drugs in the pipeline for COVID-19
Here are the potential human coronavirus vaccines/drugs pharmaceutical companies across the world are developing following the Wuhan coronavirus outbreak (COVID-19).
Janssen’s Stelara shows remission in Crohn’s disease patients
Interim results from the Phase IIIb STARDUST clinical trial have revealed that Janssen Pharmaceutical’s Stelara (ustekinumab) led to clinical remission in moderately to severely active Crohn's disease (CD) patients.
ImmunogenX starts enrolment in Phase IIb celiac disease study
Biotherapeutics company ImmunogenX has commenced patient enrolment in a Phase IIb clinical trial of Latiglutenase (IMGX003) for the treatment of celiac disease.
AbbVie reports positive data for Rinvoq in psoriatic arthritis
AbbVie has reported that the Phase III SELECT-PsA 1 study of Rinvoq (upadacitinib) has met its primary endpoint in adults with active psoriatic arthritis.
AstraZeneca studies Fasenra in three new trials for skin diseases
AstraZeneca has started three new clinical trials to evaluate monoclonal antibody Fasenra for the treatment of eosinophil-driven skin diseases.